Identification

Name
Rifaximin
Accession Number
DB01220  (APRD01218)
Type
Small Molecule
Groups
Approved, Investigational
Description

Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.

Structure
Thumb
Synonyms
  • Rifamycin L 105
  • Rifamycin L 105SV
  • Rifaxidin
  • Rifaximin
  • Rifaximina
  • Rifaximine
  • Rifaximinum
  • Rifaximinun
  • Xifaxsan
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
XifaxanTablet200 mg/1OralPhysicians Total Care, Inc.2008-12-14Not applicableUs65649 0301 03 nlmimage10 951dcafe
XifaxanTablet550 mg/1OralCarton Service, Incorporated2010-05-012017-07-19Us
XifaxanTablet550 mg/1OralCardinal Health2010-05-01Not applicableUs
XifaxanTablet550 mg/1OralPhysicians Total Care, Inc.2010-08-19Not applicableUs65649 0303 02 nlmimage10 ca3ee557
XifaxanTablet200 mg/1OralSalix Pharmaceuticals2004-07-25Not applicableUs
XifaxanTablet200 mg/1OralCarilion Materials Management2004-07-25Not applicableUs
XifaxanTablet200 mg/1OralAvera Mc Kennan Hospital2015-05-07Not applicableUs
XifaxanTablet200 mg/1OralDispensing Solutions, Inc.2004-07-25Not applicableUs
XifaxanTablet550 mg/1OralSalix Pharmaceuticals2010-05-01Not applicableUs
XifaxanTablet200 mg/1OralA S Medication Solutions2004-07-252017-06-20Us
International/Other Brands
Normix / Rifacol / Xifaxsan
Categories
UNII
L36O5T016N
CAS number
80621-81-4
Weight
Average: 785.8785
Monoisotopic: 785.352359489
Chemical Formula
C43H51N3O11
InChI Key
NZCRJKRKKOLAOJ-XRCRFVBUSA-N
InChI
InChI=1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)/b12-11+,17-15+,21-13-/t20-,22+,23+,24+,27-,35-,36+,39+,43-/m0/s1
IUPAC Name
(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,36-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6,23-dioxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.1⁴,⁷.0⁵,³⁵.0²⁶,³⁴.0²⁷,³²]heptatriaconta-1,3,5(35),9,19,21,25(36),26(34),28,30,32-undecaen-13-yl acetate
SMILES
CO[[email protected]]1\C=C\O[[email protected]@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[[email protected]](C)[[email protected]](O)[[email protected]@H](C)[[email protected]@H](O)[[email protected]@H](C)[[email protected]](OC(C)=O)[[email protected]@H]1C)C1=C(N=C5C=C(C)C=CN15)C4=C3C2=O

Pharmacology

Indication

Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in adult men and women.

Structured Indications
Pharmacodynamics

Rifaximin is a structural analog of rifampin and a non-systemic, gastrointestinal site-specific antibiotic. This non-systemic property of the drug is due to the addition of a pyridoimidazole ring, which renders it non-absorbable. Rifaximin acts by inhibiting bacterial ribonucleic acid (RNA) synthesis and contributes to restore intestinal microflora imbalance. Other studies have also shown rifaximin to be an pregnane X receptor (PXR) activator. As PXR is responsible for inhibiting the proinflammatory transcription factor NF-kappa B (NF-κB) and is inhibited in inflammatory bowel disease (IBD), rifaximin was proven to be effective for the treatment of IBS-D.

Mechanism of action

Rifaximin acts by inhibiting RNA synthesis in susceptible bacteria by binding to the beta-subunit of bacterial deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase enzyme. This results in the blockage of the translocation step that normally follows the formation of the first phosphodiester bond, which occurs in the transcription process.

TargetActionsOrganism
ADNA-directed RNA polymerase subunit beta
inhibitor
Escherichia coli (strain K12)
NNuclear receptor subfamily 1 group I member 2
agonist
Human
Absorption

Low absorption in both the fasting state and when administered within 30 minutes of a high-fat breakfast.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

In vitro drug interactions studies have shown that rifaximin, at concentrations ranging from 2 to 200 ng/mL, did not inhibit human hepatic cytochrome P450 isoenzymes: 1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, and 3A4. In an in vitro hepa-tocyte induction model, rifaximin was shown to induce cytochrome P450 3A4 (CYP3A4), an isoenzyme which rifampin is known to induce.

Route of elimination

In a mass balance study, after administration of 400 mg 14C-rifaximin orally to healthy volunteers, of the 96.94% total recovery, 96.62% of the administered radioactivity was recovered in feces almost exclusively as the unchanged drug and 0.32% was recovered in urine mostly as metabolites with 0.03% as the unchanged drug.Rifaximin accounted for 18% of radioactivity in plasma. This suggests that the absorbed rifaximin undergoes metabolism with minimal renal excretion of the unchanged drug

Half life

Approximately 6 hours.

Clearance
Not Available
Toxicity

LD50 > 2 g/kg (orally, in rats)

Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe serum concentration of Rifaximin can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Experimental
2-mercaptobenzothiazoleThe serum concentration of Rifaximin can be increased when it is combined with 2-mercaptobenzothiazole.Vet Approved
AbemaciclibThe serum concentration of Rifaximin can be increased when it is combined with Abemaciclib.Approved
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Rifaximin.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Rifaximin.Approved
AcetaminophenThe serum concentration of Rifaximin can be increased when it is combined with Acetaminophen.Approved
AfatinibThe serum concentration of Rifaximin can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Rifaximin can be increased when it is combined with Albendazole.Approved, Vet Approved
AlectinibThe serum concentration of Rifaximin can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Alfentanil can be decreased when it is combined with Rifaximin.Approved, Illicit
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Rifaximin.Approved, Withdrawn
AmantadineThe serum concentration of Rifaximin can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Rifaximin can be increased when it is combined with Aminohippuric acid.Approved, Investigational
AmiodaroneThe serum concentration of Rifaximin can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Rifaximin can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Rifaximin can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe metabolism of Amobarbital can be increased when combined with Rifaximin.Approved, Illicit
AmorolfineThe serum concentration of Rifaximin can be increased when it is combined with Amorolfine.Approved, Investigational
Amphotericin BThe serum concentration of Rifaximin can be increased when it is combined with Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Rifaximin can be increased when it is combined with Amprenavir.Approved
AmrinoneThe serum concentration of Amrinone can be decreased when it is combined with Rifaximin.Approved
AmsacrineThe serum concentration of Rifaximin can be increased when it is combined with Amsacrine.Approved
AnidulafunginThe serum concentration of Rifaximin can be increased when it is combined with Anidulafungin.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Rifaximin.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Rifaximin.Approved, Investigational
ArtemetherThe serum concentration of Rifaximin can be increased when it is combined with Artemether.Approved
AstemizoleThe serum concentration of Rifaximin can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Rifaximin can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Rifaximin can be increased when it is combined with Atenolol.Approved
AtorvastatinThe serum concentration of Rifaximin can be increased when it is combined with Atorvastatin.Approved
AtovaquoneThe serum concentration of Atovaquone can be decreased when it is combined with Rifaximin.Approved
AzelastineThe serum concentration of Rifaximin can be increased when it is combined with Azelastine.Approved
AzelnidipineThe serum concentration of Azelnidipine can be decreased when it is combined with Rifaximin.Approved, Investigational
AzimilideThe serum concentration of Azimilide can be decreased when it is combined with Rifaximin.Investigational
AzithromycinThe serum concentration of Rifaximin can be increased when it is combined with Azithromycin.Approved
Bafilomycin A1The serum concentration of Rifaximin can be increased when it is combined with Bafilomycin A1.Experimental
BarbexacloneThe metabolism of Barbexaclone can be increased when combined with Rifaximin.Experimental
BarbitalThe metabolism of Barbital can be increased when combined with Rifaximin.Illicit
BarnidipineThe serum concentration of Barnidipine can be decreased when it is combined with Rifaximin.Approved
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Rifaximin.Experimental
BencyclaneThe serum concentration of Bencyclane can be decreased when it is combined with Rifaximin.Experimental
BenidipineThe serum concentration of Benidipine can be decreased when it is combined with Rifaximin.Approved, Investigational
BenzocaineThe serum concentration of Rifaximin can be increased when it is combined with Benzocaine.Approved
Benzoic AcidThe serum concentration of Rifaximin can be increased when it is combined with Benzoic Acid.Approved
BepridilThe serum concentration of Rifaximin can be increased when it is combined with Bepridil.Approved, Withdrawn
BetaxololThe serum concentration of Betaxolol can be decreased when it is combined with Rifaximin.Approved
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Rifaximin.Approved
BifonazoleThe serum concentration of Rifaximin can be increased when it is combined with Bifonazole.Approved, Investigational
BiperidenThe serum concentration of Rifaximin can be increased when it is combined with Biperiden.Approved, Investigational
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Rifaximin.Approved
BoceprevirThe serum concentration of Rifaximin can be increased when it is combined with Boceprevir.Approved, Withdrawn
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Rifaximin.Approved
BosutinibThe serum concentration of Rifaximin can be increased when it is combined with Bosutinib.Approved
Brefeldin AThe serum concentration of Rifaximin can be increased when it is combined with Brefeldin A.Experimental
BromocriptineThe serum concentration of Rifaximin can be increased when it is combined with Bromocriptine.Approved, Investigational
BucindololThe serum concentration of Bucindolol can be decreased when it is combined with Rifaximin.Investigational
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Rifaximin.Experimental, Investigational
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Rifaximin.Approved
BuprenorphineThe serum concentration of Rifaximin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Rifaximin.Approved, Investigational
ButenafineThe serum concentration of Rifaximin can be increased when it is combined with Butenafine.Approved
ButoconazoleThe serum concentration of Rifaximin can be increased when it is combined with Butoconazole.Approved
CabazitaxelThe serum concentration of Rifaximin can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Rifaximin can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Rifaximin can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Rifaximin can be increased when it is combined with Candesartan.Experimental
Candesartan cilexetilThe serum concentration of Rifaximin can be increased when it is combined with Candesartan cilexetil.Approved
CandicidinThe serum concentration of Rifaximin can be increased when it is combined with Candicidin.Withdrawn
Capric acidThe serum concentration of Rifaximin can be increased when it is combined with Capric acid.Experimental
CaptoprilThe serum concentration of Rifaximin can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Rifaximin can be increased when it is combined with Carbamazepine.Approved, Investigational
CarbomycinThe metabolism of Rifaximin can be decreased when combined with Carbomycin.Vet Approved
CarboxyamidotriazoleThe serum concentration of Carboxyamidotriazole can be decreased when it is combined with Rifaximin.Investigational
CaroverineThe serum concentration of Caroverine can be decreased when it is combined with Rifaximin.Experimental
CarteololThe serum concentration of Carteolol can be decreased when it is combined with Rifaximin.Approved
CarvedilolThe serum concentration of Rifaximin can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Rifaximin can be increased when it is combined with Caspofungin.Approved
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Rifaximin.Approved, Investigational
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Rifaximin.Withdrawn
CeruleninThe serum concentration of Rifaximin can be increased when it is combined with Cerulenin.Approved
ChloroquineThe serum concentration of Rifaximin can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Rifaximin.Investigational, Withdrawn
ChloroxineThe serum concentration of Rifaximin can be increased when it is combined with Chloroxine.Approved
ChlorpromazineThe serum concentration of Rifaximin can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Rifaximin can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Rifaximin can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
CholesterolThe serum concentration of Rifaximin can be increased when it is combined with Cholesterol.Experimental, Investigational
CiclopiroxThe serum concentration of Rifaximin can be increased when it is combined with Ciclopirox.Approved, Investigational
CilazaprilThe serum concentration of Rifaximin can be increased when it is combined with Cilazapril.Approved
CilnidipineThe serum concentration of Cilnidipine can be decreased when it is combined with Rifaximin.Approved, Investigational
CimetidineThe serum concentration of Rifaximin can be increased when it is combined with Cimetidine.Approved
CinnarizineThe serum concentration of Cinnarizine can be decreased when it is combined with Rifaximin.Approved, Investigational
CiprofloxacinThe serum concentration of Rifaximin can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Rifaximin can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Rifaximin can be increased when it is combined with Clarithromycin.Approved
ClevidipineThe serum concentration of Clevidipine can be decreased when it is combined with Rifaximin.Approved
ClofazimineThe serum concentration of Rifaximin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Rifaximin can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Rifaximin is combined with Clopidogrel.Approved, Nutraceutical
CloranololThe serum concentration of Cloranolol can be decreased when it is combined with Rifaximin.Experimental
ClorindioneThe metabolism of Clorindione can be increased when combined with Rifaximin.Experimental
ClotrimazoleThe serum concentration of Rifaximin can be increased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Rifaximin can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Rifaximin can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Rifaximin can be increased when it is combined with Colforsin.Experimental, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Rifaximin.Approved
CordycepinThe serum concentration of Rifaximin can be increased when it is combined with Cordycepin.Investigational
CrizotinibThe serum concentration of Rifaximin can be increased when it is combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Rifaximin can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Rifaximin can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
DaclatasvirThe serum concentration of Rifaximin can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Rifaximin can be increased when it is combined with Dactinomycin.Approved
DapsoneThe metabolism of Dapsone can be increased when combined with Rifaximin.Approved, Investigational
DarodipineThe serum concentration of Darodipine can be decreased when it is combined with Rifaximin.Experimental
DasatinibThe serum concentration of Rifaximin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Rifaximin can be increased when it is combined with Daunorubicin.Approved
DelavirdineThe metabolism of Delavirdine can be increased when combined with Rifaximin.Approved
DesipramineThe serum concentration of Rifaximin can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Rifaximin can be increased when it is combined with Desloratadine.Approved, Investigational
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Rifaximin.Approved
DexamethasoneThe serum concentration of Rifaximin can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Rifaximin can be increased when it is combined with Dextromethorphan.Approved
DichloropheneThe serum concentration of Rifaximin can be increased when it is combined with Dichlorophene.Vet Approved
DiclofenacThe serum concentration of Rifaximin can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Rifaximin.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Rifaximin.Approved, Investigational
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Rifaximin.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Rifaximin.Approved, Investigational
DigoxinThe serum concentration of Rifaximin can be increased when it is combined with Digoxin.Approved
DihydroergotamineThe serum concentration of Rifaximin can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Rifaximin can be increased when it is combined with Diltiazem.Approved
DiphenadioneThe metabolism of Diphenadione can be increased when combined with Rifaximin.Experimental
DipyridamoleThe serum concentration of Rifaximin can be increased when it is combined with Dipyridamole.Approved
DotarizineThe serum concentration of Dotarizine can be decreased when it is combined with Rifaximin.Investigational
DoxazosinThe serum concentration of Rifaximin can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Rifaximin can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Rifaximin can be increased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Rifaximin can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Rifaximin can be increased when it is combined with Dronedarone.Approved
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Rifaximin.Approved
EconazoleThe serum concentration of Rifaximin can be increased when it is combined with Econazole.Approved
EfinaconazoleThe serum concentration of Rifaximin can be increased when it is combined with Efinaconazole.Approved
EfonidipineThe serum concentration of Efonidipine can be decreased when it is combined with Rifaximin.Approved, Investigational
EnalaprilThe serum concentration of Rifaximin can be increased when it is combined with Enalapril.Approved, Vet Approved
EnasidenibThe serum concentration of Rifaximin can be increased when it is combined with Enasidenib.Approved
EnzalutamideThe serum concentration of Rifaximin can be increased when it is combined with Enzalutamide.Approved
EpanololThe serum concentration of Epanolol can be decreased when it is combined with Rifaximin.Experimental
EperisoneThe serum concentration of Eperisone can be decreased when it is combined with Rifaximin.Approved, Investigational
ErgonovineThe serum concentration of Rifaximin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Rifaximin can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Rifaximin can be increased when it is combined with Erythromycin.Approved, Vet Approved
EsmololThe serum concentration of Esmolol can be decreased when it is combined with Rifaximin.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Rifaximin.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Rifaximin can be increased when it is combined with Estramustine.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Rifaximin.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Rifaximin.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Rifaximin.Approved
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Rifaximin.Withdrawn
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Rifaximin.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Rifaximin.Approved, Investigational
EtoposideThe serum concentration of Rifaximin can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Rifaximin can be increased when it is combined with Etravirine.Approved
FelodipineThe serum concentration of Rifaximin can be increased when it is combined with Felodipine.Approved, Investigational
FendilineThe serum concentration of Fendiline can be decreased when it is combined with Rifaximin.Withdrawn
FentanylThe serum concentration of Rifaximin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe serum concentration of Rifaximin can be increased when it is combined with Fenticonazole.Experimental
FexofenadineThe serum concentration of Rifaximin can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Rifaximin can be increased when it is combined with Fidaxomicin.Approved
FluconazoleThe serum concentration of Rifaximin can be increased when it is combined with Fluconazole.Approved
FlucytosineThe serum concentration of Rifaximin can be increased when it is combined with Flucytosine.Approved
FluindioneThe metabolism of Fluindione can be increased when combined with Rifaximin.Investigational
FlunarizineThe serum concentration of Flunarizine can be decreased when it is combined with Rifaximin.Approved
FluoxetineThe serum concentration of Rifaximin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Rifaximin can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Rifaximin can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Rifaximin can be increased when it is combined with Flurazepam.Approved, Illicit
FlutrimazoleThe serum concentration of Rifaximin can be increased when it is combined with Flutrimazole.Experimental
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Rifaximin.Approved
FluvoxamineThe serum concentration of Rifaximin can be increased when it is combined with Fluvoxamine.Approved, Investigational
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Rifaximin.Approved, Investigational
GallopamilThe serum concentration of Gallopamil can be decreased when it is combined with Rifaximin.Investigational
GefitinibThe serum concentration of Rifaximin can be increased when it is combined with Gefitinib.Approved, Investigational
GenisteinThe serum concentration of Rifaximin can be increased when it is combined with Genistein.Investigational
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Rifaximin.Approved, Investigational
GlecaprevirThe serum concentration of Rifaximin can be increased when it is combined with Glecaprevir.Approved
GlyburideThe serum concentration of Rifaximin can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Rifaximin can be increased when it is combined with Glycerin.Approved, Investigational
GlyphosateThe serum concentration of Rifaximin can be increased when it is combined with Glyphosate.Experimental
Gramicidin DThe serum concentration of Rifaximin can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Rifaximin can be increased when it is combined with Grepafloxacin.Investigational, Withdrawn
GriseofulvinThe serum concentration of Rifaximin can be increased when it is combined with Griseofulvin.Approved, Vet Approved
HachimycinThe serum concentration of Rifaximin can be increased when it is combined with Hachimycin.Experimental
HaloperidolThe serum concentration of Rifaximin can be increased when it is combined with Haloperidol.Approved
HaloproginThe serum concentration of Rifaximin can be increased when it is combined with Haloprogin.Approved, Withdrawn
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Rifaximin.Withdrawn
HexetidineThe serum concentration of Rifaximin can be increased when it is combined with Hexetidine.Approved, Investigational
HexobarbitalThe metabolism of Hexobarbital can be increased when combined with Rifaximin.Approved
HydrocortisoneThe serum concentration of Rifaximin can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IdelalisibThe serum concentration of Rifaximin can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Rifaximin.Approved
ImipramineThe serum concentration of Rifaximin can be increased when it is combined with Imipramine.Approved
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Rifaximin.Withdrawn
IndinavirThe serum concentration of Rifaximin can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Rifaximin can be increased when it is combined with Indomethacin.Approved, Investigational
IsavuconazoniumThe serum concentration of Rifaximin can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe serum concentration of Rifaximin can be increased when it is combined with Isoconazole.Approved
IsoniazidRifaximin may increase the hepatotoxic activities of Isoniazid.Approved
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Rifaximin.Approved
ItraconazoleThe serum concentration of Rifaximin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Rifaximin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Rifaximin can be increased when it is combined with Ivermectin.Approved, Vet Approved
JosamycinThe metabolism of Rifaximin can be decreased when combined with Josamycin.Approved, Investigational
KetamineThe serum concentration of Rifaximin can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Rifaximin can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinThe metabolism of Rifaximin can be decreased when combined with Kitasamycin.Experimental
LabetalolThe serum concentration of Labetalol can be decreased when it is combined with Rifaximin.Approved
LacidipineThe serum concentration of Lacidipine can be decreased when it is combined with Rifaximin.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Rifaximin.Approved, Investigational
LandiololThe serum concentration of Landiolol can be decreased when it is combined with Rifaximin.Investigational
LansoprazoleThe serum concentration of Rifaximin can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Rifaximin can be increased when it is combined with Lapatinib.Approved, Investigational
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Rifaximin.Approved, Investigational
LetermovirThe serum concentration of Rifaximin can be increased when it is combined with Letermovir.Approved
LevobunololThe serum concentration of Levobunolol can be decreased when it is combined with Rifaximin.Approved
LevofloxacinThe serum concentration of Rifaximin can be increased when it is combined with Levofloxacin.Approved, Investigational
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Rifaximin.Approved, Investigational
LidocaineThe serum concentration of Rifaximin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LidoflazineThe serum concentration of Lidoflazine can be decreased when it is combined with Rifaximin.Experimental
LomitapideThe serum concentration of Rifaximin can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Rifaximin can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Rifaximin can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Rifaximin can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Rifaximin can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Rifaximin can be increased when it is combined with Lovastatin.Approved, Investigational
LumacaftorThe serum concentration of Rifaximin can be increased when it is combined with Lumacaftor.Approved
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Rifaximin.Investigational
Magnesium SulfateThe serum concentration of Magnesium Sulfate can be decreased when it is combined with Rifaximin.Approved, Vet Approved
ManidipineThe serum concentration of Manidipine can be decreased when it is combined with Rifaximin.Approved, Investigational
MaprotilineThe serum concentration of Rifaximin can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Rifaximin can be increased when it is combined with Mebendazole.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Rifaximin.Approved, Investigational
MefloquineThe serum concentration of Rifaximin can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Rifaximin can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MepartricinThe serum concentration of Rifaximin can be increased when it is combined with Mepartricin.Experimental
MepindololThe serum concentration of Mepindolol can be decreased when it is combined with Rifaximin.Experimental
MeprobamateThe serum concentration of Rifaximin can be increased when it is combined with Meprobamate.Approved, Illicit
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Rifaximin.Approved
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Rifaximin.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Rifaximin.Experimental
MethohexitalThe metabolism of Methohexital can be increased when combined with Rifaximin.Approved
MethylphenobarbitalThe metabolism of Methylphenobarbital can be increased when combined with Rifaximin.Approved
MetipranololThe serum concentration of Metipranolol can be decreased when it is combined with Rifaximin.Approved
MetoprololThe serum concentration of Rifaximin can be increased when it is combined with Metoprolol.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Rifaximin.Experimental
MibefradilThe serum concentration of Rifaximin can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MicafunginThe serum concentration of Rifaximin can be increased when it is combined with Micafungin.Approved, Investigational
MiconazoleThe serum concentration of Rifaximin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Rifaximin can be increased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Rifaximin can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe serum concentration of Rifaximin can be increased when it is combined with Miltefosine.Approved
MitomycinThe serum concentration of Rifaximin can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Rifaximin can be increased when it is combined with Mitoxantrone.Approved, Investigational
MonensinThe serum concentration of Rifaximin can be increased when it is combined with Monensin.Vet Approved
MorphineThe serum concentration of Rifaximin can be increased when it is combined with Morphine.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Rifaximin.Approved
MyxothiazolThe serum concentration of Rifaximin can be increased when it is combined with Myxothiazol.Experimental
NadololThe serum concentration of Nadolol can be decreased when it is combined with Rifaximin.Approved
NaftifineThe serum concentration of Rifaximin can be increased when it is combined with Naftifine.Approved
NaftopidilThe serum concentration of Naftopidil can be decreased when it is combined with Rifaximin.Investigational
NaltrexoneThe serum concentration of Rifaximin can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Rifaximin can be increased when it is combined with Naringenin.Experimental
NatamycinThe serum concentration of Rifaximin can be increased when it is combined with Natamycin.Approved
NebivololThe serum concentration of Nebivolol can be decreased when it is combined with Rifaximin.Approved, Investigational
NelfinavirThe serum concentration of Rifaximin can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Rifaximin can be increased when it is combined with Neostigmine.Approved, Vet Approved
NicardipineThe serum concentration of Rifaximin can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Rifaximin can be increased when it is combined with Nifedipine.Approved
NifuratelThe serum concentration of Rifaximin can be increased when it is combined with Nifuratel.Experimental
NiguldipineThe serum concentration of Niguldipine can be decreased when it is combined with Rifaximin.Experimental
Nikkomycin ZThe serum concentration of Rifaximin can be increased when it is combined with Nikkomycin Z.Investigational
NilotinibThe serum concentration of Rifaximin can be increased when it is combined with Nilotinib.Approved, Investigational
NiludipineThe serum concentration of Niludipine can be decreased when it is combined with Rifaximin.Experimental
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Rifaximin.Approved, Investigational
NimesulideThe serum concentration of Nimesulide can be decreased when it is combined with Rifaximin.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Rifaximin.Approved
NisoldipineThe serum concentration of Rifaximin can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Rifaximin can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Rifaximin can be increased when it is combined with Nitrendipine.Approved, Investigational
NitroxolineThe serum concentration of Rifaximin can be increased when it is combined with Nitroxoline.Approved
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Rifaximin.Approved
NorgestimateThe serum concentration of Norgestimate can be decreased when it is combined with Rifaximin.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Rifaximin.Approved
NystatinThe serum concentration of Rifaximin can be increased when it is combined with Nystatin.Approved, Vet Approved
OleandomycinThe metabolism of Rifaximin can be decreased when combined with Oleandomycin.Vet Approved
OmeprazoleThe serum concentration of Rifaximin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OmoconazoleThe serum concentration of Rifaximin can be increased when it is combined with Omoconazole.Experimental
OtiloniumThe serum concentration of Otilonium can be decreased when it is combined with Rifaximin.Experimental, Investigational
OxiconazoleThe serum concentration of Rifaximin can be increased when it is combined with Oxiconazole.Approved
OxprenololThe serum concentration of Oxprenolol can be decreased when it is combined with Rifaximin.Approved
P-NitrophenolThe serum concentration of Rifaximin can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Rifaximin can be increased when it is combined with Paclitaxel.Approved, Vet Approved
pafuramidineThe serum concentration of Rifaximin can be increased when it is combined with pafuramidine.Investigational
Palmitic AcidThe serum concentration of Rifaximin can be increased when it is combined with Palmitic Acid.Approved, Experimental
PantoprazoleThe serum concentration of Rifaximin can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Rifaximin can be increased when it is combined with Paroxetine.Approved, Investigational
PenbutololThe serum concentration of Penbutolol can be decreased when it is combined with Rifaximin.Approved, Investigational
PentamidineThe serum concentration of Rifaximin can be increased when it is combined with Pentamidine.Approved
PentobarbitalThe metabolism of Pentobarbital can be increased when combined with Rifaximin.Approved, Vet Approved
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Rifaximin.Approved, Investigational
PerindoprilThe serum concentration of Rifaximin can be increased when it is combined with Perindopril.Approved
PhenindioneThe metabolism of Phenindione can be increased when combined with Rifaximin.Approved, Investigational
PhenobarbitalThe metabolism of Phenobarbital can be increased when combined with Rifaximin.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Rifaximin.Approved, Investigational
PibrentasvirThe serum concentration of Rifaximin can be increased when it is combined with Pibrentasvir.Approved
PimozideThe serum concentration of Rifaximin can be increased when it is combined with Pimozide.Approved
PinaveriumThe serum concentration of Pinaverium can be decreased when it is combined with Rifaximin.Approved
PindololThe serum concentration of Pindolol can be decreased when it is combined with Rifaximin.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Rifaximin.Approved
Platelet Activating FactorThe serum concentration of Platelet Activating Factor can be decreased when it is combined with Rifaximin.Experimental
PonatinibThe serum concentration of Rifaximin can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Rifaximin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololThe serum concentration of Practolol can be decreased when it is combined with Rifaximin.Approved
PravastatinThe serum concentration of Rifaximin can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Rifaximin can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Rifaximin can be increased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe serum concentration of Pregabalin can be decreased when it is combined with Rifaximin.Approved, Illicit, Investigational
PrenylamineThe serum concentration of Prenylamine can be decreased when it is combined with Rifaximin.Withdrawn
PrimidoneThe metabolism of Primidone can be increased when combined with Rifaximin.Approved, Vet Approved
ProbenecidThe serum concentration of Rifaximin can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Rifaximin can be increased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Rifaximin can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Rifaximin can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Rifaximin can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Rifaximin can be increased when it is combined with Protriptyline.Approved
PyrrolnitrinThe serum concentration of Rifaximin can be increased when it is combined with Pyrrolnitrin.Experimental
QuercetinThe serum concentration of Rifaximin can be increased when it is combined with Quercetin.Experimental, Investigational
QuinacrineThe serum concentration of Rifaximin can be increased when it is combined with Quinacrine.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Rifaximin.Approved
QuinineThe serum concentration of Rifaximin can be increased when it is combined with Quinine.Approved
RadicicolThe serum concentration of Rifaximin can be increased when it is combined with Radicicol.Experimental
RamelteonThe metabolism of Ramelteon can be increased when combined with Rifaximin.Approved, Investigational
RanitidineThe serum concentration of Rifaximin can be increased when it is combined with Ranitidine.Approved
ReboxetineThe serum concentration of Rifaximin can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Rifaximin can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Rifaximin can be increased when it is combined with Reserpine.Approved, Investigational
RifampicinThe serum concentration of Rifaximin can be increased when it is combined with Rifampicin.Approved
RilpivirineThe serum concentration of Rifaximin can be increased when it is combined with Rilpivirine.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Rifaximin.Approved, Investigational
RitonavirThe serum concentration of Rifaximin can be increased when it is combined with Ritonavir.Approved, Investigational
RolapitantThe serum concentration of Rifaximin can be increased when it is combined with Rolapitant.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Rifaximin.Approved
Salicylhydroxamic AcidThe serum concentration of Rifaximin can be increased when it is combined with Salicylhydroxamic Acid.Experimental
Salicylic acidThe serum concentration of Rifaximin can be increased when it is combined with Salicylic acid.Approved, Vet Approved
SaquinavirThe serum concentration of Rifaximin can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Rifaximin.Approved
ScopolamineThe serum concentration of Rifaximin can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Secobarbital can be increased when combined with Rifaximin.Approved, Vet Approved
SelegilineThe serum concentration of Rifaximin can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertaconazoleThe serum concentration of Rifaximin can be increased when it is combined with Sertaconazole.Approved
SertralineThe serum concentration of Rifaximin can be increased when it is combined with Sertraline.Approved
SimeprevirThe serum concentration of Rifaximin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Rifaximin can be increased when it is combined with Simvastatin.Approved
SinefunginThe serum concentration of Rifaximin can be increased when it is combined with Sinefungin.Experimental
SirolimusThe serum concentration of Rifaximin can be increased when it is combined with Sirolimus.Approved, Investigational
SolithromycinThe metabolism of Rifaximin can be decreased when combined with Solithromycin.Investigational
SorafenibThe serum concentration of Rifaximin can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Rifaximin.Approved
SpironolactoneThe serum concentration of Rifaximin can be increased when it is combined with Spironolactone.Approved
StaurosporineThe serum concentration of Rifaximin can be increased when it is combined with Staurosporine.Experimental
SulconazoleThe serum concentration of Rifaximin can be increased when it is combined with Sulconazole.Approved
SulfinpyrazoneThe serum concentration of Rifaximin can be increased when it is combined with Sulfinpyrazone.Approved
SumatriptanThe serum concentration of Rifaximin can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Rifaximin can be increased when it is combined with Sunitinib.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Rifaximin.Approved
TacrineThe serum concentration of Rifaximin can be increased when it is combined with Tacrine.Investigational, Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Rifaximin.Approved, Investigational
TalinololThe serum concentration of Talinolol can be decreased when it is combined with Rifaximin.Investigational
TamoxifenThe metabolism of Tamoxifen can be increased when combined with Rifaximin.Approved
Taurocholic AcidThe serum concentration of Rifaximin can be increased when it is combined with Taurocholic Acid.Experimental
TavaboroleThe serum concentration of Rifaximin can be increased when it is combined with Tavaborole.Approved
TelaprevirThe serum concentration of Rifaximin can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Rifaximin can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Rifaximin can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Rifaximin.Approved
TerazosinThe serum concentration of Rifaximin can be increased when it is combined with Terazosin.Approved
TerbinafineThe serum concentration of Rifaximin can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe serum concentration of Rifaximin can be increased when it is combined with Terconazole.Approved
TerfenadineThe serum concentration of Rifaximin can be increased when it is combined with Terfenadine.Withdrawn
TerodilineThe serum concentration of Terodiline can be decreased when it is combined with Rifaximin.Experimental
TertatololThe serum concentration of Tertatolol can be decreased when it is combined with Rifaximin.Experimental
TestosteroneThe serum concentration of Rifaximin can be increased when it is combined with Testosterone.Approved, Investigational
TetrahydropalmatineThe serum concentration of Tetrahydropalmatine can be decreased when it is combined with Rifaximin.Investigational
ThiamylalThe metabolism of Thiamylal can be increased when combined with Rifaximin.Approved, Vet Approved
ThiopentalThe metabolism of Thiopental can be increased when combined with Rifaximin.Approved, Vet Approved
ThymolThe serum concentration of Rifaximin can be increased when it is combined with Thymol.Approved
TicagrelorThe serum concentration of Rifaximin can be increased when it is combined with Ticagrelor.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Rifaximin.Approved
TioclomarolThe metabolism of Tioclomarol can be increased when combined with Rifaximin.Experimental
TioconazoleThe serum concentration of Rifaximin can be increased when it is combined with Tioconazole.Approved
TolciclateThe serum concentration of Rifaximin can be increased when it is combined with Tolciclate.Experimental
Tolfenamic AcidThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Rifaximin.Approved
TolnaftateThe serum concentration of Rifaximin can be increased when it is combined with Tolnaftate.Approved, Vet Approved
TolvaptanThe serum concentration of Rifaximin can be increased when it is combined with Tolvaptan.Approved
TranilastThe serum concentration of Tranilast can be decreased when it is combined with Rifaximin.Approved, Investigational
TrifluoperazineThe serum concentration of Rifaximin can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Rifaximin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Rifaximin can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimetrexateThe serum concentration of Rifaximin can be increased when it is combined with Trimetrexate.Approved, Investigational
TrimipramineThe serum concentration of Rifaximin can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Rifaximin can be increased when it is combined with Troleandomycin.Approved
TylosinThe metabolism of Rifaximin can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be decreased when it is combined with Rifaximin.Approved, Experimental
VelpatasvirThe serum concentration of Rifaximin can be increased when it is combined with Velpatasvir.Approved
VenlafaxineThe serum concentration of Rifaximin can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Rifaximin can be increased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Rifaximin can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Rifaximin can be increased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Rifaximin can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetineThe serum concentration of Vinpocetine can be decreased when it is combined with Rifaximin.Investigational
VoriconazoleThe serum concentration of Rifaximin can be increased when it is combined with Voriconazole.Approved, Investigational
VoxilaprevirThe serum concentration of Rifaximin can be increased when it is combined with Voxilaprevir.Approved
WarfarinThe metabolism of Warfarin can be increased when combined with Rifaximin.Approved
XylometazolineThe serum concentration of Xylometazoline can be decreased when it is combined with Rifaximin.Approved
ZiconotideThe serum concentration of Ziconotide can be decreased when it is combined with Rifaximin.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Rifaximin.Approved
ZimelidineThe serum concentration of Rifaximin can be increased when it is combined with Zimelidine.Withdrawn
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Rifaximin.Approved
Food Interactions
Not Available

References

Synthesis Reference

Giuseppe Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini, "Polymorphic forms of rifaximin, processes for their production and uses thereof." U.S. Patent US20050272754, issued December 08, 2005.

US20050272754
General References
  1. Cottreau J, Baker SF, DuPont HL, Garey KW: Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. Expert Rev Anti Infect Ther. 2010 Jul;8(7):747-60. doi: 10.1586/eri.10.58. [PubMed:20586560]
  2. Williams R, Bass N: Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety. Rev Gastroenterol Disord. 2005;5 Suppl 1:S10-8. [PubMed:15976747]
  3. Koo HL, DuPont HL: Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol. 2010 Jan;26(1):17-25. doi: 10.1097/MOG.0b013e328333dc8d. [PubMed:19881343]
  4. Pakyz AL: Rifaximin: a new treatment for travelers' diarrhea. Ann Pharmacother. 2005 Feb;39(2):284-9. Epub 2004 Dec 14. [PubMed:15598963]
  5. Jalan R: Rifaximin in hepatic encephalopathy: more than just a non-absorbable antibiotic? J Hepatol. 2010 Sep;53(3):580-2. doi: 10.1016/j.jhep.2010.05.002. Epub 2010 May 31. [PubMed:20561708]
  6. Lawrence KR, Klee JA: Rifaximin for the treatment of hepatic encephalopathy. Pharmacotherapy. 2008 Aug;28(8):1019-32. doi: 10.1592/phco.28.8.1019. [PubMed:18657018]
  7. Layer P, Andresen V: Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers' diarrhoea. Aliment Pharmacol Ther. 2010 Jun;31(11):1155-64. doi: 10.1111/j.1365-2036.2010.04296.x. Epub 2010 Mar 11. [PubMed:20331580]
  8. Ojetti V, Lauritano EC, Barbaro F, Migneco A, Ainora ME, Fontana L, Gabrielli M, Gasbarrini A: Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):675-82. doi: 10.1517/17425250902973695. [PubMed:19442033]
  9. Scarpignato C, Pelosini I: Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy. 2005;51 Suppl 1:36-66. [PubMed:15855748]
  10. Gillis JC, Brogden RN: Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs. 1995 Mar;49(3):467-84. [PubMed:7774516]
  11. Koo HL, Dupont HL, Huang DB: The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea. Ther Clin Risk Manag. 2009;5:841-8. Epub 2009 Nov 2. [PubMed:19898648]
  12. DuPont HL: Systematic review: prevention of travellers' diarrhoea. Aliment Pharmacol Ther. 2008 May;27(9):741-51. doi: 10.1111/j.1365-2036.2008.03647.x. Epub 2008 Feb 14. [PubMed:18284650]
  13. Romero-Gomez M: Pharmacotherapy of hepatic encephalopathy in cirrhosis. Expert Opin Pharmacother. 2010 Jun;11(8):1317-27. doi: 10.1517/14656561003724721. [PubMed:20384539]
  14. Scarpignato C, Pelosini I: Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion. 2006;73 Suppl 1:13-27. Epub 2006 Feb 8. [PubMed:16498249]
  15. Pimentel M: Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs. 2009 Mar;18(3):349-58. doi: 10.1517/13543780902780175 . [PubMed:19243285]
External Links
Human Metabolome Database
HMDB15351
KEGG Drug
D02554
PubChem Compound
6436173
PubChem Substance
46508705
ChemSpider
10482302
BindingDB
50347620
ChEBI
75246
ChEMBL
CHEMBL1617
Therapeutic Targets Database
DAP001006
PharmGKB
PA164752443
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Rifaximin
ATC Codes
A07AA11 — RifaximinD06AX11 — Rifaximin
AHFS Codes
  • 08:12.28.30 — Rifamycins
FDA label
Download (478 KB)
MSDS
Download (58.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentEnd Stage Renal Disease (ESRD)1
1CompletedNot AvailablePharmacokinetics1
1CompletedTreatmentMalignancies / Transplantation, Bone Marrow1
1CompletedTreatmentPrimary Sclerosing Cholangitis (PSC)1
1Unknown StatusTreatmentGulf War Syndrome1
1, 2Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
1, 2CompletedTreatmentMinimal Hepatic Encephalopathy1
1, 2RecruitingPreventionCirrhotic Patients Undergoing TIPS Placement1
1, 2RecruitingTreatmentCrohn's Disease (CD)1
2Active Not RecruitingTreatmentChronic Hepatitis C Infection1
2CompletedPreventionDiarrhea1
2CompletedTreatmentInfection, Human Immunodeficiency Virus I1
2CompletedTreatmentIrritable Bowel Syndrome (IBS)2
2Enrolling by InvitationTreatmentAlcoholic Hepatitis (AH)1
2RecruitingTreatmentAdherent-invasive E. Coli / Crohn's Disease (CD)1
2RecruitingTreatmentCirrhoses, Liver1
2RecruitingTreatmentCrohn's Disease (CD)1
2RecruitingTreatmentHeart Failure With Reduced Ejection Fraction (HFrEF)1
2RecruitingTreatmentMajor Liver Resection / Malignant Liver Disease1
2Unknown StatusTreatmentChronic Hepatitis C Infection / Hepatic Encephalopathy / Liver Cirrhosis1
2Unknown StatusTreatmentHepatic Encephalopathy1
2WithdrawnTreatmentRosaceas1
2, 3CompletedTreatmentFunctional Dyspepsia1
2, 3RecruitingTreatmentIrritable Bowel Syndrome (IBS)1
2, 3RecruitingTreatmentLiver Cirrhosis / Portal Hypertension1
2, 3RecruitingTreatmentParkinson's Disease (PD) / Small Intestinal Bacterial Overgrowth1
3Active Not RecruitingTreatmentRectal Carcinoma1
3CompletedPreventionDiarrhea2
3CompletedPreventionDiarrhoea1
3CompletedPreventionHepatic Encephalopathy2
3CompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
3CompletedTreatmentClostridium Infections / Diarrhea1
3CompletedTreatmentDiarrhea1
3CompletedTreatmentDiarrhoea Predominant Irritable Bowel Syndrome1
3CompletedTreatmentLiver Cirrhosis1
3CompletedTreatmentNon-Constipation Irritable Bowel Syndrome2
3CompletedTreatmentParkinson's Disease (PD)1
3Not Yet RecruitingPreventionCrohn's Disease (CD)1
3Not Yet RecruitingTreatmentAscites / Liver Cirrhosis / Peritonitis1
3Not Yet RecruitingTreatmentSevere Alcoholic Hepatitis1
3RecruitingPreventionAscites / Liver Cirrhosis / Spontaneous Bacterial Peritonitis (SBP)1
3RecruitingPreventionCrohn's Disease (CD)1
3RecruitingTreatmentLiver Cirrhosis / Portal Hypertension1
3TerminatedTreatmentTravelers' Diarrhea1
3WithdrawnPreventionSpontaneous Bacterial Peritonitis (SBP)1
3WithdrawnTreatmentHepatic Encephalopathy1
4CompletedBasic ScienceAscites / Liver Cirrhosis1
4CompletedBasic ScienceCommon Variable Immunodeficiency (CVID)1
4CompletedPreventionHepatic Encephalopathy1
4CompletedTreatmentDiverticular disorders1
4CompletedTreatmentHepatic Encephalopathy / Liver Cirrhosis1
4CompletedTreatmentTravelers' Diarrhea1
4Not Yet RecruitingTreatmentCovert Hepatic Encephalopathy1
4RecruitingPreventionChronic Kidney Disease (CKD)1
4RecruitingPreventionClostridium Difficile Infection (CDI)1
4RecruitingTreatmentHepatic Encephalopathy1
4RecruitingTreatmentIrritable Bowel Syndrome (IBS)1
4RecruitingTreatmentLiver Cirrhosis1
4TerminatedTreatmentHepatic Encephalopathy / Liver Cirrhosis / Portal Hypertension1
4TerminatedTreatmentNAFLD / Nonalcoholic Fatty Liver Disease / Nonalcoholic Steatohepatitis1
4Unknown StatusPreventionLiver Cirrhosis1
4Unknown StatusTreatmentLiver Cirrhosis / Renal Failure1
4WithdrawnPreventionChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV)1
4WithdrawnTreatmentTravelers' Diarrhea1
Not AvailableCompletedNot AvailableTropical Enteropathy1
Not AvailableCompletedDiagnosticHepatic Encephalopathy / Liver Cirrhosis1
Not AvailableCompletedDiagnosticIntestinal FDG Uptake1
Not AvailableCompletedTreatmentAcute on Chronic Liver Failure With Hepatic Encephalopathy / Acute-On-Chronic Liver Failure1
Not AvailableCompletedTreatmentBMI >30 kg/m2 / Diabetes1
Not AvailableCompletedTreatmentChronic Abdominal Discomfort / Functional Dyspepsia / Small Intestinal Bacterial Overgrowth1
Not AvailableCompletedTreatmentChronic Abdominal Pain / Small Intestinal Bacterial Overgrowth1
Not AvailableCompletedTreatmentCirrhosis Related Parkinsonism / Hepatic/Cirrhosis Related Parkinsonism1
Not AvailableCompletedTreatmentConstipation-Predominant Irritable Bowel Syndrome1
Not AvailableCompletedTreatmentFatty Liver / Steatohepatitis1
Not AvailableCompletedTreatmentGluten Enteropathy1
Not AvailableCompletedTreatmentHepatic Encephalopathy2
Not AvailableCompletedTreatmentIBS1
Not AvailableCompletedTreatmentIrritable Bowel Syndrome (IBS) / Small Intestinal Bacterial Overgrowth1
Not AvailableCompletedTreatmentUlcerative Colitis (UC)1
Not AvailableRecruitingBasic ScienceChronic Hepatitis C Virus (HCV) Infection / Liver Cirrhosis1
Not AvailableRecruitingDiagnosticDumping Syndrome / Gastric Resection / Hypoglycemia / Oesophagectomy1
Not AvailableRecruitingPreventionEsophageal and Gastric Varices / Hemorrhage, Gastrointestinal / Liver Cirrhosis1
Not AvailableRecruitingPreventionFunctional Bowel Disorders / Reactive Arthritis / Travelers' Diarrhea1
Not AvailableRecruitingTreatmentEsophageal and Gastric Varices / Hemorrhage, Gastrointestinal / Liver Cirrhosis1
Not AvailableRecruitingTreatmentLiver Cirrhosis / Small Intestinal Bacterial Overgrowth1
Not AvailableRecruitingTreatmentRefractory Hepatic Encephalopathy1
Not AvailableTerminatedDiagnosticDigestive System Diseases / Gastrointestinal Diseases / Small Bowel Bacterial Overgrowth / Stomach Diseases1
Not AvailableTerminatedTreatmentAcute Watery Diarrhea / Dysentery/Febrile Diarrhea1
Not AvailableUnknown StatusNot AvailableSimple Diverticular Disease1
Not AvailableUnknown StatusTreatmentHepatopulmonary Syndrome1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral200 mg/1
TabletOral550 mg/1
TabletOral550 mg
Prices
Unit descriptionCostUnit
Xifaxan 550 mg tablet22.4USD tablet
Xifaxan 200 mg tablet8.97USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7928115No2009-07-242029-07-24Us
US8741904No2006-02-272026-02-27Us
US7612199No2004-06-192024-06-19Us
US8853231No2004-06-192024-06-19Us
US8158644No2004-06-192024-06-19Us
US8193196No2007-09-022027-09-02Us
US7906542No2005-06-012025-06-01Us
US8158781No2004-06-192024-06-19Us
US7045620No2004-06-192024-06-19Us
US8518949No2006-02-272026-02-27Us
US8835452No2004-06-192024-06-19Us
US7902206No2004-06-192024-06-19Us
US8829017No2009-07-242029-07-24Us
US8642573No2009-10-022029-10-02Us
US8969398No2009-10-022029-10-02Us
US8946252No2009-07-242029-07-24Us
US7915275No2005-02-232025-02-23Us
US8309569No2009-07-182029-07-18Us
US7718608No1999-08-112019-08-11Us
US7452857No1999-08-112019-08-11Us
US6861053No1999-08-112019-08-11Us
US7605240No1999-08-112019-08-11Us
US7935799No1999-08-112019-08-11Us
US9271968No2006-02-272026-02-27Us
US9421195No2010-03-102030-03-10Us
US9629828No2009-07-242029-07-24Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP2.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00738 mg/mLALOGPS
logP4.94ALOGPS
logP4.37ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)3.66ChemAxon
pKa (Strongest Basic)11.87ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count11ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area198.38 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity216.69 m3·mol-1ChemAxon
Polarizability82.26 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.646
Blood Brain Barrier-0.973
Caco-2 permeable-0.6301
P-glycoprotein substrateSubstrate0.6681
P-glycoprotein inhibitor INon-inhibitor0.6985
P-glycoprotein inhibitor IINon-inhibitor0.7134
Renal organic cation transporterNon-inhibitor0.9533
CYP450 2C9 substrateNon-substrate0.8256
CYP450 2D6 substrateNon-substrate0.8783
CYP450 3A4 substrateSubstrate0.5651
CYP450 1A2 substrateNon-inhibitor0.7129
CYP450 2C9 inhibitorNon-inhibitor0.7393
CYP450 2D6 inhibitorNon-inhibitor0.875
CYP450 2C19 inhibitorNon-inhibitor0.7684
CYP450 3A4 inhibitorNon-inhibitor0.8904
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7729
Ames testNon AMES toxic0.6276
CarcinogenicityNon-carcinogens0.9055
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6259 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.994
hERG inhibition (predictor II)Non-inhibitor0.721
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as macrolactams. These are cyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. They are nitrogen analogues (the a nitrogen atom replacing the o atom of the cyclic carboxylic acid group ) of the naturally occurring macrolides.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Macrolactams
Sub Class
Not Available
Direct Parent
Macrolactams
Alternative Parents
Naphthofurans / Naphthols and derivatives / Benzimidazoles / Benzofurans / Coumarans / Imidazo[1,2-a]pyridines / Aryl alkyl ketones / Methylpyridines / Ketals / N-substituted imidazoles
show 14 more
Substituents
Macrolactam / Naphthofuran / 1-naphthol / Naphthalene / Benzimidazole / Benzofuran / Coumaran / Imidazo[1,2-a]pyridine / Aryl alkyl ketone / Aryl ketone
show 33 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
acetate ester, organic heterohexacyclic compound, lactam, semisynthetic derivative, macrocycle, cyclic ketal, rifamycin (CHEBI:75246)

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Ribonucleoside binding
Specific Function
DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates.
Gene Name
rpoB
Uniprot ID
P0A8V2
Uniprot Name
DNA-directed RNA polymerase subunit beta
Molecular Weight
150631.165 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Vitali B, Turroni S, Dal Piaz F, Candela M, Wasinger V, Brigidi P: Genetic and proteomic characterization of rifaximin resistance in Bifidobacterium infantis BI07. Res Microbiol. 2007 May;158(4):355-62. Epub 2007 Feb 22. [PubMed:17408927]
  4. Ojetti V, Lauritano EC, Barbaro F, Migneco A, Ainora ME, Fontana L, Gabrielli M, Gasbarrini A: Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):675-82. doi: 10.1517/17425250902973695. [PubMed:19442033]
  5. Koo HL, Dupont HL, Huang DB: The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea. Ther Clin Risk Manag. 2009;5:841-8. Epub 2009 Nov 2. [PubMed:19898648]
  6. Scarpignato C, Pelosini I: Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion. 2006;73 Suppl 1:13-27. Epub 2006 Feb 8. [PubMed:16498249]
  7. Pimentel M: Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs. 2009 Mar;18(3):349-58. doi: 10.1517/13543780902780175 . [PubMed:19243285]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
Gene Name
NR1I2
Uniprot ID
O75469
Uniprot Name
Nuclear receptor subfamily 1 group I member 2
Molecular Weight
49761.245 Da
References
  1. Cheng J, Shah YM, Ma X, Pang X, Tanaka T, Kodama T, Krausz KW, Gonzalez FJ: Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther. 2010 Oct;335(1):32-41. doi: 10.1124/jpet.110.170225. Epub 2010 Jul 13. [PubMed:20627999]
  2. Ma X, Shah YM, Guo GL, Wang T, Krausz KW, Idle JR, Gonzalez FJ: Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther. 2007 Jul;322(1):391-8. Epub 2007 Apr 18. [PubMed:17442842]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:33